2025-10-04 - Analysis Report
Okay, here's an analysis of Merck & Co. (MRK) based on the provided data, presented in a clear and concise manner with an emphasis on the key takeaways.

## Merck & Co. (MRK) Analysis

**0. Executive Summary:**

This report analyzes Merck & Co. (MRK), a leading pharmaceutical company, focusing on its stock performance, recent market data, analyst opinions, earnings, and financial health.  The analysis reveals recent positive momentum in the stock price, driven by positive news and analyst sentiment, but also highlights concerns about long-term underperformance compared to the S&P 500 and potentially overbought conditions.

**1. Performance vs. S&P 500 (VOO):**

*   **MRK Ticker:** MRK
*   **Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and markets medicines, vaccines, and animal health products.
*   **MRK Cumulative Return:** 5.45%
*   **VOO Cumulative Return:** 98.51%
*   **Relative Deviation:** (Max: 23.9, Min: -103.9, Current: -92.6, Relative Deviation: 8.8)

**Analysis:**

MRK has significantly underperformed the S&P 500 over the analyzed period. The current deviation is -92.6, with a relative deviation of 8.8, indicating the current value is near the bottom range of historical deviation. This suggests MRK has historically lagged the overall market significantly.

**Alpha, Beta Analysis Table:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 1.0% | 68.5% | -28.0% | 0.0 | 134.1 |
| 2016-2018  | 36.0% | 69.8% | 21.0% | -0.0 | 182.1 |
| 2017-2019  | 40.0% | 69.8% | 18.0% | 0.3 | 216.8 |
| 2018-2020  | 16.0% | 79.6% | -8.0% | 0.3 | 195.0 |
| 2019-2021  | 2.0% | 79.6% | -44.0% | 0.7 | 191.4 |
| 2020-2022  | 15.0% | 79.6% | 16.0% | 0.7 | 277.1 |
| 2021-2023  | 33.0% | 79.6% | 31.0% | 0.3 | 272.3 |
| 2022-2024  | -4.0% | 79.6% | -25.0% | 0.2 | 248.5 |
| 2023-2025  | -44.0% | 71.5% | -107.0% | 1.5 | 222.8 |

**Analysis:**

*   **CAGR:** Wide variation in Compound Annual Growth Rate, ranging from negative to positive territory.
*   **MDD:** Consistently high Maximum Drawdown, indicating significant risk/volatility.
*   **Alpha:** Mostly negative alpha values suggest underperformance relative to the market. Recent value is -107%.
*   **Beta:** Low Beta values (generally below 1) indicate lower sensitivity to market movements. The value is recently at 1.5.
*   **Cap(B):** Market capitalization is in the range of hundreds of billions.

**2. Recent Stock Price Movement:**

*   **Current Price:** 89.19
*   **Previous Close:** 89.51
*   **Change:** -0.36
*   **5-day Moving Average:** 86.591
*   **20-day Moving Average:** 82.7977
*   **60-day Moving Average:** 82.7615

**Analysis:**

The current price is slightly down from the previous close, but significantly above the 5, 20, and 60-day moving averages. This suggests a recent upward trend in the stock price.

**3. Market Risk Indicators & Expected Return:**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 72.81 (Overbought territory)
*   **PPO:** 1.29
*   **Hybrid Signal:**  Cash_0%_Buy 100% of cash (35 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)
*   **Delta_Previous_Relative_Divergence:** 8.8 (+): Short-term increase
*   **Expected Return (%):** -64.5 (Expected outperformance relative to S&P 500 with long-term, regular investment)

**Analysis:**

*   **MRI:** The high MRI suggests the stock is considered a relatively safe investment at the moment.
*   **RSI:** The high RSI value indicates the stock may be overbought and a pullback is possible.
*   **Delta_Previous_Relative_Divergence:** Indicates short-term upward momentum.
*   **Expected Return:** Negative expected return suggests that, with consistent long-term investment, there is an anticipation to underperform the S&P 500.
*   **Recent Price Change:** The small price change (-0.36) doesn't indicate a major volatility event.

**4. Recent News & Significant Events:**

*   **Positive Catalysts:** News headlines indicate positive sentiment towards MRK due to AI-trade lifts, Healthcare Gains Following Pfizer Deal. Also, MRK Stock Up Nearly 14% So Far This Week.
*   **Analyst Sentiment:** "What Does Wall Street Think About Merck & Co. (MRK)?" suggests a focus on analyst opinions.
*   **Comparison:** "5 Large Cap Drug Stocks: Values or Traps?" suggests comparing MRK to its peers.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.00)
*   **Opinions:** 25
*   **Target Price:** Avg: 101.60 / High: 141.00 / Low: 82.00
*   **Recent Rating Changes:** No specific changes provided.

**Analysis:**

Analysts generally have a "Buy" rating on MRK with an average target price of $101.60, suggesting potential upside from the current price.

**5. Recent Earnings Analysis:**

| 날짜         | EPS  | 매출       |
|--------------|------|------------|
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2024-08-05 | 2.15 | 16.11 B$   |
| 2025-08-05 | 2.15 | 16.11 B$   |

**Analysis:**

*   **Revenue:** Revenue has fluctuated in the range of $15.53B to $16.66B over the past few quarters.
*   **EPS:** EPS has also fluctuated, indicating some variability in profitability.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30 | $15.81B   | 77.50%        |
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-06-30 | $48.99B   | 9.04% |
| 2025-03-31 | $48.34B   | 10.51% |
| 2024-12-31 | $46.31B   | 8.08% |
| 2024-09-30 | $44.50B   | 7.09% |
| 2024-06-30 | $43.58B   | 12.52% |

**Analysis:**

*   **Revenue:** Relatively stable revenue figures.
*   **Profit Margin:** High and consistent profit margins, indicating strong profitability.
*   **Equity:** Increasing equity suggests the company is growing its asset base.
*   **ROE:** Fluctuating ROE indicates changes in the company's efficiency in generating profits from equity.

**7. Overall Analysis:**

*   **Underperformance:** MRK has significantly underperformed the S&P 500 historically.
*   **Recent Momentum:** Recent news and price action suggest positive momentum.
*   **Analyst Sentiment:** Analysts are generally positive with a "Buy" rating and potential upside.
*   **Financial Health:**  Strong profit margins and increasing equity indicate good financial health.
*   **Overbought Condition:** The RSI indicates the stock may be overbought in the short term.

**Conclusion:**

MRK presents a mixed picture. While it has shown recent positive momentum and analysts are optimistic, its historical underperformance compared to the S&P 500 is a concern. The high RSI suggests caution in the short term. The strong financial health and positive analyst sentiment are encouraging for long-term prospects.  Investors should weigh the potential for continued growth against the historical underperformance and consider the possibility of a short-term pullback due to the overbought condition.
